These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37610627)

  • 1. Immunohistochemical expression of PRAME in 485 cases of epithelial tubo-ovarian tumors.
    Šafanda A; Kendall Bártů M; Michálková R; Stružinská I; Drozenová J; Fabián P; Hausnerová J; Laco J; Matěj R; Škapa P; Švajdler M; Špůrková Z; Méhes G; Dundr P; Němejcová K
    Virchows Arch; 2023 Oct; 483(4):509-516. PubMed ID: 37610627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors.
    Němejcová K; Šafanda A; Bártů MK; Michálková R; Drozenová J; Fabian P; Hausnerová J; Laco J; Matěj R; Méhes G; Škapa P; Stružinská I; Dundr P
    Diagn Pathol; 2023 Feb; 18(1):32. PubMed ID: 36855066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma.
    Chen H; Molberg K; Strickland AL; Castrillon DH; Carrick K; Jiang Q; Niu S; Rivera-Colon G; Gwin K; Hinson S; Lea J; Miller DS; Zheng W; Lucas E
    Am J Surg Pathol; 2020 Aug; 44(8):1050-1060. PubMed ID: 32384321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors.
    Němejcová K; Bártů MK; Michálková R; Drozenová J; Fabian P; Fadare O; Hausnerová J; Laco J; Matěj R; Méhes G; Singh N; Stolnicu S; Škapa P; Švajdler M; Stružinská I; Cibula D; Kocian R; Lax SF; McCluggage WG; Dundr P
    Diagn Pathol; 2023 Feb; 18(1):15. PubMed ID: 36740684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRAME Expression in Cancer. A Systematic Immunohistochemical Study of >5800 Epithelial and Nonepithelial Tumors.
    Kaczorowski M; Chłopek M; Kruczak A; Ryś J; Lasota J; Miettinen M
    Am J Surg Pathol; 2022 Nov; 46(11):1467-1476. PubMed ID: 35973038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anterior gradient protein 2 (AGR2) is an independent prognostic factor in ovarian high-grade serous carcinoma.
    Darb-Esfahani S; Fritzsche F; Kristiansen G; Weichert W; Sehouli J; Braicu I; Dietel M; Denkert C
    Virchows Arch; 2012 Aug; 461(2):109-16. PubMed ID: 22752467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma.
    Chui MH; Momeni Boroujeni A; Mandelker D; Ladanyi M; Soslow RA
    Mod Pathol; 2021 Feb; 34(2):490-501. PubMed ID: 32801341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PRAME Expression in Endometrioid and Serous Endometrial Carcinoma: A Potential Immunotherapeutic Target and Possible Diagnostic Pitfall.
    Coppock JD; Gradecki SE; Mills AM
    Int J Gynecol Pathol; 2023 Jan; 42(1):35-42. PubMed ID: 35512215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 11. SOX6 Expression Is Sensitive for Peritoneal Epithelioid Malignant Mesothelioma, But Not Specific in the Differential Diagnosis With Tubo-ovarian Serous Neoplasia.
    Chapel DB; Hirsch MS
    Am J Surg Pathol; 2022 Feb; 46(2):213-219. PubMed ID: 34411029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mammary serine protease inhibitor and CD138 immunohistochemical expression in ovarian serous and clear cell carcinomas.
    Hasby EA
    Tumour Biol; 2016 Apr; 37(4):4889-900. PubMed ID: 26526579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive in situ analysis of ALDH1 and SOX2 reveals increased expression of stem cell markers in high-grade serous carcinomas compared to low-grade serous carcinomas and atypical proliferative serous tumors.
    Fischer AK; Pham DL; Bösmüller H; Lengerke C; Wagner P; Bachmann C; Beschorner C; Perner S; Kommoss S; Fend F; Staebler A
    Virchows Arch; 2019 Oct; 475(4):479-488. PubMed ID: 31451895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomas.
    Köbel M; Yang RZ; Kang EY; Al-Shamma Z; Cook LS; Kinloch M; Carey MS; Hopkins L; Nelson GS; McManus KJ; Vizeacoumar FS; Vizeacoumar FJ; Freywald A; Fu Y; Reuss DE; Lee CH
    Gynecol Oncol; 2023 Nov; 178():80-88. PubMed ID: 37820398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatic Genomic and Transcriptomic Characterization of Primary Ovarian Serous Borderline Tumors and Low-Grade Serous Carcinomas.
    Stružinská I; Hájková N; Hojný J; Krkavcová E; Michálková R; Bui QH; Matěj R; Laco J; Drozenová J; Fabian P; Škapa P; Špůrková Z; Cibula D; Frühauf F; Jirásek T; Zima T; Méhes G; Kendall Bártů M; Němejcová K; Dundr P
    J Mol Diagn; 2024 Apr; 26(4):257-266. PubMed ID: 38280423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian Low-grade Serous Carcinoma: A Clinicopathologic Study of 33 Cases With Primary Surgery Performed at a Single Institution.
    Okoye E; Euscher ED; Malpica A
    Am J Surg Pathol; 2016 May; 40(5):627-35. PubMed ID: 26900814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of MTAP immunohistochemistry loss of expression in ovarian serous borderline tumors as a potential marker for prognosis and progression.
    Nilforoushan N; Moatamed NA
    Ann Diagn Pathol; 2020 Oct; 48():151582. PubMed ID: 32866902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nicotinamide N-methyltransferase overexpression may be associated with poor prognosis in ovarian cancer.
    Harmankaya İ; Akar S; Uğraş S; Güler AH; Ezveci H; Aydoğdu M; Çelik Ç
    J Obstet Gynaecol; 2021 Feb; 41(2):248-253. PubMed ID: 32285726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression and promotor methylation of p73 gene in ovarian epithelial tumors].
    Zhang YL; Guo XR; Shen DH; Cheng YX; Liang XD; Chen YX; Wang Y
    Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):33-8. PubMed ID: 22455848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas.
    Shappell HW; Riopel MA; Smith Sehdev AE; Ronnett BM; Kurman RJ
    Am J Surg Pathol; 2002 Dec; 26(12):1529-41. PubMed ID: 12459620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.